Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 601–700 of 1,025
Aldehyde oxidase and its role as a drug metabolizing enzyme
Dalvie, D., & Di, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.011 · Cited by 96
Application of Nanoparticles in Cancer Treatment: A Concise Review
Sell, M., Lopes, A. R., Escudeiro, M., Esteves, B., Monteiro, A. R., Trindade, T., & Cruz‐Lopes, L. (2023) · Nanomaterials · doi:10.3390/nano13212887 · Cited by 102
“The scientific community leans on the use of nanotechnology, as a strategy with great potential to overcome these challenges [10], specifically by enhancing the drug delivery into target sites, increasing efficacy and reducing side effects [11].”
BackgroundLaminar ventricular myocardium on a microelectrode array-based chip
Kujala, V. J., Pasqualini, F. S., Goss, J. A., Nawroth, J. C., & Parker, K. K. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00324a · Cited by 91
Engineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
“Despite the large amount of money (~$3-5B) and time (12-15 years) invested during drug development, ~90% of compounds fail during clinical trials, with one-third of such failures attributed to organ toxicity [3].”
BackgroundLiu, Q., Waltz, S., Woodruff, G., Ouyang, J., Israel, M. A., Herrera, C., Sarsoza, F., Tanzi, R. E., Koo, E. H., Ringman, J. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2482 · Cited by 91
Nadanaciva, S., Rana, P., Beeson, G. C., Chen, D., Ferrick, D. A., Beeson, C., & Will, Y. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9446-z · Cited by 91
“It is estimated that at least 30 % of compound attrition at the clinical stage of drug development is a result of toxicity (Kola and Landis 2004).”
BackgroundProgesterone neuroprotection: The background of clinical trial failure
Schumacher, M., Denier, C., Oudinet, J., Adams, D., & Guennoun, R. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.11.010 · Cited by 98
Nagasundaram, N., Yapp, E. K. Y., Le, N. Q. K., Kamaraj, B., Al‐Subaie, A. M., & Yeh, H. (2019) · BioMed Research International · doi:10.1155/2019/8427042 · Cited by 97
“Furthermore, only 5% of anticancer drugs getting into Phase I clinical trials are often approved [47].”
BackgroundProgress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
Bruno, R., Bottino, D. C., de Alwis, D. P., Fojo, A. T., Guedj, J., Liu, C., Swanson, K. R., Zheng, J., Zheng, Y., & Jin, J. Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0287 · Cited by 91
“However, this approach has long been challenged (2), far too many phase III trials fail to achieve their endpoint (3) and an increased scrutiny needs to be given to how go/no-go decisions are made.”
BackgroundAnticancer drug synergy prediction in understudied tissues using transfer learning
Kim, Y., Zheng, S., Tang, J., Jim Zheng, W., Li, Z., & Jiang, X. (2021) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa212 · Cited by 87
The ultimate model organism: progress in experimental medicine
Littman, B. H., & Williams, S. A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1800 · Cited by 93
A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor
Klinghoffer, R. A., Bahrami, S. B., Hatton, B. A., Frazier, J. P., Moreno-Gonzalez, A., Strand, A. D., Kerwin, W. S., Casalini, J. R., Thirstrup, D. J., You, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7489 · Cited by 90
“Attrition rates for new oncology drugs in clinical trials are higher than those of almost all other therapeutic areas, and survival rates for patientswith advanced cancers are persistently low (1, 2).”
Large-scale Direct Targeting for Drug Repositioning and Discovery
Zheng, C., Guo, Z., Huang, C., Wu, Z., Li, Y., Chen, X., Fu, Y., Ru, J., Shar, P. A., Wang, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep11970 · Cited by 96
“To obtain a reliable data set, we filtered the PLPs with the following steps: (1) deleting the redundant PLPs based on the protein sequences and the ligand Inchkey; (2) removing the PLPs of which Ki and IC50 values are unavailable or the average value of them larger than 10 μ M; (3) expunging the smaller ligand-set si…”
MethodMetabolic Network Prediction of Drug Side Effects
Shaked, I., Oberhardt, M., Atias, N., Sharan, R., & Ruppin, E. (2016) · Cell Systems · doi:10.1016/j.cels.2016.03.001 · Cited by 101
Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human
Basit, A., Neradugomma, N. K., Wolford, C. C., Fan, P. W., Murray, B. P., Takahashi, R., Khojasteh, S. C., Smith, B. J., Heyward, S. A., Totah, R. A., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00559 · Cited by 92
Expanding medicinal chemistry space
Barker, A. J., Kettle, J. G., Nowak, T., & Pease, J. E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.008 · Cited by 106
Impact of biomarker development on drug safety assessment
Marrer, E., & Dieterle, F. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.015 · Cited by 93
The Generation, Detection, and Effects of Reactive Drug Metabolites
Stachulski, A. V., Baillie, T. A., Kevin Park, B., Scott Obach, R., Dalvie, D. K., Williams, D. P., Srivastava, A., Regan, S. L., Antoine, D. J., Goldring, C. E. P., et al. (2013) · Medicinal Research Reviews · doi:10.1002/med.21273 · Cited by 88
“173 The synthesis of GSH involves two steps: (1) the (rate-limiting) conjugation of L-glutamate to cysteine via the γ -glutamylcysteine ligase catalytic (GCLC) subunit to form γ -glutamylcysteine and (2) the conjugation of glycine to γ -glutamylcysteine, via GSH synthetase, to yield GSH.”
BackgroundMethodNardo, G. D., & Gilardi, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131215901 · Cited by 104
“(1) The increase of the substrate specificity by protein engineering; (2) The improvement of the catalytic performance (KM, kcat, coupling efficiency) of P450 BM3 toward drugs; (3) The substitution of the costly NADPH cofactor; (4) The immobilization and scale-up of the process for industrial application.”
BackgroundComputational Drug Repurposing: Current Trends
Karaman, B., & Sippl, W. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530100332 · Cited by 96
Fluorescent ligands: Bringing light to emerging GPCR paradigms
Soave, M., Briddon, S. J., Hill, S. J., & Stoddart, L. A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14953 · Cited by 97
“…that measuring the affinity at equilibrium may not be the best predictor of the in vivo efficacy of a compound, as a number of clinically approved drugs show non-equilibrium modes of binding (Hothersall, Brown, Dale, & Rawlins, 2016; Kola & Landis, 2004; Schuetz et al., 2017; Waring et al., 2015).”
BackgroundWagner‐Rousset, E., Bednarczyk, A., Bussat, M., Colas, O., Corvaïa, N., Schaeffer‐Reiss, C., DORSSELAER, A. V., & Beck, A. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.03.032 · Cited by 89
Advances in the Process Development of Biocatalytic Processes
Tufvesson, P., Ramos, J. L., Al‐Haque, N., Gernaey, K. V., & Woodley, J. M. (2013) · Organic Process Research & Development · doi:10.1021/op4001675 · Cited by 88
Patient-derived xenografts as in vivo models for research in urological malignancies
Inoue, T., Terada, N., Kobayashi, T., & Ogawa, O. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.19 · Cited by 91
Beyond the 3 Rs to a More Comprehensive Framework of Principles for Animal Research Ethics
DeGrazia, D., & Beauchamp, T. L. (2019) · ILAR Journal · doi:10.1093/ilar/ilz011 · Cited by 103
Impact of ion class and time on oral drug molecular properties
Leeson, P. D., St-Gallay, S. A., & Wenlock, M. C. (2010) · MedChemComm · doi:10.1039/c0md00157k · Cited by 87
Chimeric mice with humanized liver
Katoh, M., Tateno, C., Yoshizato, K., & Yokoi, T. (2007) · Toxicology · doi:10.1016/j.tox.2007.11.012 · Cited by 91
Gittelman, M. (2016) · Research Policy · doi:10.1016/j.respol.2016.01.007 · Cited by 98
Deep Learning to Predict the Formation of Quinone Species in Drug Metabolism
Hughes, T. B., & Swamidass, S. J. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00385 · Cited by 95
Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery
Braam, S. R., Passier, R., & Mummery, C. L. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.001 · Cited by 86
Usta, O. B., McCarty, W. J., Bale, S., Hegde, M., Jindal, R., Bhushan, A., Golberg, I., & Yarmush, M. L. (2015) · TECHNOLOGY · doi:10.1142/s2339547815300012 · Cited by 85
Patient‑derived xenograft mouse models: A high fidelity tool for individualized medicine (Review)
Xu, C., Li, X., Liu, P., Li, M., & Luo, F. (2018) · Oncology Letters · doi:10.3892/ol.2018.9583 · Cited by 112
“Though >2/3 of agents are tested safely in phase I of clinical trials, the predictive accuracy of drug effectiveness is unsatisfactory in phase II due to the loss of heterogeneity and the specific cell microenvironment and alterations to the mechanism of tumorigenesis (1-3).”
BackgroundSwift, R. V., & Amaro, R. E. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12074 · Cited by 93
“Subsequently, the pharmaceutical industry has committed significant efforts to understand the molecular basis of bioavailability and pharmacokinetics, and as a result, the rate of clinical compound failure attributed to these two factors has decreased substantially (2).”
BackgroundAkabane, T., Tanaka, K., Irie, M., Terashita, S., & Teramura, T. (2011) · Xenobiotica · doi:10.3109/00498254.2010.549970 · Cited by 93
“Indeed, a phase 1 study found that poor exposure of drug candidates was the most significant cause of candidate attrition, accounting for ~ 40% of all candidate loss in the early 1990s (Kola and Landis, 2004).”
BackgroundSykes, M. L., Baell, J. B., Kaiser, M., Chatelain, E., Moawad, S. R., Ganame, D., Ioset, J., & Avery, V. M. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001896 · Cited by 93
“This is particularly evident when one takes into account the toxicity of traditional treatments, the inability of the newer less toxic combination therapies to treat both subspecies or both disease stages, and the historical 90% failure rate of drugs entering the clinic to reach the market [18].”
BackgroundUnderstanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science
Antoine, D. J., Williams, D. P., & Park, B. K. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.11.1415 · Cited by 87
“Adverse drug reactions (ADRs) represent one of the major clinical challenges to patients’ health and are a key reason for attrition in drug development [1-3] .”
BackgroundNew Cocrystals of Hydrochlorothiazide: Optimizing Solubility and Membrane Diffusivity
Gopi, S. P., Banik, M., & Desiraju, G. R. (2016) · Crystal Growth & Design · doi:10.1021/acs.cgd.6b01540 · Cited by 86
Benz, M., Molla, M. R., Böser, A., Rosenfeld, A., & Levkin, P. A. (2019) · Nature Communications · doi:10.1038/s41467-019-10685-0 · Cited by 95
Reducing the Risk of Drug Attrition Associated with Physicochemical Properties
Leeson, P. D., & Empfield, J. R. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45024-1 · Cited by 88
Drug Substance and Former Structure Property Relationships in 15 Diverse Pharmaceutical Co-Crystals
Stanton, M. K., Tufekcic, S., Morgan, C., & Bak, A. (2009) · Crystal Growth & Design · doi:10.1021/cg8005019 · Cited by 85
Can we discover pharmacological promiscuity early in the drug discovery process?
Peters, J., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., Migeon, J., Fischer, H., Guba, W., et al. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.001 · Cited by 91
Subdiffusion in Membrane Permeation of Small Molecules
Chipot, C. J., & Comer, J. R. (2016) · Scientific Reports · doi:10.1038/srep35913 · Cited by 85
“β ∂ = ∂ ∂ − c z t D z D z F z t c z t ( , ) [ ( ) ( ) ( , )] ( , ), (2) t z z”
A Biomimetic Human Gut‐on‐a‐Chip for Modeling Drug Metabolism in Intestine
Guo, Y., Li, Z., Su, W., Wang, L., Zhu, Y., & Qin, J. (2018) · Artificial Organs · doi:10.1111/aor.13163 · Cited by 88
Metrics for antibody therapeutics development
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.6.13603 · Cited by 85
“Antibody therapeutics also have higher approval success rates and similar development phase lengths compared with those of small molecule drugs.(1-4) As evidenced by global sales that exceeded US $1 bn in 2009 for each of at least nine mAb products, physicians and patients have accepted mAbs despite the fact that the…”
BackgroundYamamoto, Y., Välitalo, P. A. J., Huntjens, D. R. H., Proost, J. H., Vermeulen, A., Krauwinkel, W. J. J., Beukers, M. W., van den Berg, D., Hartman, R., Wong, Y. C., et al. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12250 · Cited by 93
“We added new components: (1) an acidic subcellular compartment representing lysosomes to account for pH-dependent drug distribution; (2) a brain microvascular compartment (brainMV) to account for CBF vs.”
MethodEvolution of commercially available compounds for HTS
Volochnyuk, D. M., Ryabukhin, S. V., Moroz, Y. S., Savych, O., Chuprina, A., Horvath, D., Zabolotna, Y., Varnek, A. A., & Judd, D. B. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.10.016 · Cited by 84
Haney, M., Vallée, M., Fabre, S., Collins, S. L., Zanese, M., Campistron, G., Arout, C. A., Foltin, R. W., Cooper, Z. D., Kearney-Ramos, T. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02381-w · Cited by 85
Spirocyclic compounds as innovative tools in drug discovery for medicinal chemists
Varela, M. T., Dias, G. G., Oliveira, L. F. G., de Oliveira, R. G., Aguiar, F. D., Nogueira, J. P., Cruz, L. R., & Dias, L. C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117368 · Cited by 84
Clinical Pharmacology During Pregnancy
(2013) · Elsevier eBooks · doi:10.1016/c2010-0-67194-x · Cited by 90
Excitation–contraction coupling of human induced pluripotent stem cell-derived cardiomyocytes
Kane, C., Couch, L. S., & Terracciano, C. M. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00059 · Cited by 91
“Up to 90% of compounds that pass pre-clinical screening fail at the highly expensive clinical trial level, with around one third showing unforeseen sideeffects (Kola and Landis, 2004).”
BackgroundWhat does the aromatic ring number mean for drug design?
Ward, S. E., & Beswick, P. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.932346 · Cited by 84
“During the last decade, the pharmaceutical industry has increased its focus on addressing the issue of attrition in company pipelines largely prompted by the question posed by Kola and Landis in their 2004 paper [16]: Can the pharmaceutical industry reduce attrition rates? This publication prompted rapid analysis of p…”
BackgroundExploring Polypharmacology Using a ROCS-Based Target Fishing Approach
AbdulHameed, M. D. M., Chaudhury, S., Singh, N. P., Sun, H., Wallqvist, A., & Tawa, G. J. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci2003544 · Cited by 87
Prenatal stress as possible aetiogenetic factor of homosexuality in human males.
Dörner, G., Geier, T., Ahrens, L., Krell, L., Münx, G., Sieler, H., Kittner, E., & Müller, H. (1980) · PubMed · Cited by 92
Lam, S. H., Mathavan, S., Tong, Y., Li, H., Karuturi, R. K. M., Wu, Y. S., Vega, V. B., Liu, E. T., & Gong, Z. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000121 · Cited by 83
“This will enable researchers to better understand the potential liabilities of new compounds before advancing them to clinical test and may help shift attrition upstream [2,47,48] or before allowing contact with the public or releasing them to the environment.”
BackgroundWang, K., Lei, Y., Xia, D., Xu, P., Zhu, T., 江, 鐘., & Ma, Y. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110755 · Cited by 89
Non-antibiotic pharmaceuticals promote conjugative plasmid transfer at a community-wide level
Wang, Y., Yu, Z., Ding, P., Lu, J., Klümper, U., Murray, A. K., Gaze, W. H., & Guo, J. (2022) · Microbiome · doi:10.1186/s40168-022-01314-y · Cited by 86
“This may be due to different mechanisms of action of these non-antibiotic pharmaceuticals [58], thus imposing various metabolic fitness in microbial communities [59].”
BackgroundStegemann, S., Moreton, C., Svanbäck, S., Box, K. J., Motte, G., & Paudel, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103344 · Cited by 91
Lim, H., Chen, J., Cook, K., Sensenhauser, C., Silva, J., & Evans, D. C. (2008) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3504 · Cited by 84
Black, M. D., Varty, G. B., Arad, M., Barak, S., Levie, A. D., Boulay, D., Pichat, P., Griebel, G., & Weiner, I. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1289-2 · Cited by 89
“However, in the domain of schizophrenia drug discovery, there are fears that simple reversal of an acute psychomimetic challenge may not be infallible, and, additionally, the most frequent reason for attrition in clinical trials is lack of efficacy (Kola and Landis 2004).”
BackgroundPhase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice
Kinders, R. J., Parchment, R. E., Ji, J. H., Kummar, S., Murgo, A. J., Gutierrez, M. E., Collins, J. M., Rubinstein, L., Pickeral, O. K., Steinberg, S. M., et al. (2007) · Molecular Interventions · doi:10.1124/mi.7.6.9 · Cited by 83
Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes
Lauer, B., Tuschl, G., Kling, M., & Mueller, S. O. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.10.031 · Cited by 83
QSAR Modeling of Tox21 Challenge Stress Response and Nuclear Receptor Signaling Toxicity Assays
Capuzzi, S. J., Politi, R., Isayev, O., Farag, S., & Tropsha, A. (2016) · Frontiers in Environmental Science · doi:10.3389/fenvs.2016.00003 · Cited by 80
“In addition, the inability to recognize potentially toxic substances during the initial steps of drug development contributes to the failure of promising pharmaceutical leads in more than 30% of human clinical trials (Kola and Landis, 2004).”
BackgroundLanthaler, K., Bilsland, E., Dobson, P. D., Moss, H. J., Pir, P., Kell, D. B., & Oliver, S. G. (2011) · BMC Biology · doi:10.1186/1741-7007-9-70 · Cited by 84
“Of the many reasons for the attrition of candidate drugs during the development process, toxicity or lack of efficacy in vivo are among the most frequent [1,2].”
BackgroundMembrane research beyond materials science
Beuscher, U., Kappert, E. J., & Wijmans, J. G. (2021) · Journal of Membrane Science · doi:10.1016/j.memsci.2021.119902 · Cited by 83
Kinders, R. J., Hollingshead, M. G., Khin, S. A., Rubinstein, L., Tomaszewski, J. E., Doroshow, J. H., & Parchment, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0214 · Cited by 82
“Barely 5% of all investigational new drug applications for novel molecular agents in oncology advance from the investigational phase to registration (1).”
BackgroundSystems biology beyond networks: Generating order from disorder through self-organization
Saetzler, K., Sonnenschein, C., & Soto, A. M. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.04.004 · Cited by 90
Is the Pharmaceutical Industry in a Productivity Crisis?
Cockburn, I. (2006) · Innovation Policy and the Economy · doi:10.1086/ipe.7.25056188 · Cited by 82
Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein
Belda, O., & Targett‐Adams, P. (2012) · Virus Research · doi:10.1016/j.virusres.2012.09.007 · Cited by 81
Measuring behavior of animal models: faults and remedies
Fonio, E., Golani, I., & Benjamini, Y. (2012) · Nature Methods · doi:10.1038/nmeth.2252 · Cited by 86
A Structure-Based Model for Predicting Serum Albumin Binding
Lexa, K. W., Dolghih, E., & Jacobson, M. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093323 · Cited by 89
Carden, C. P., Sarker, D., Postel-Vinay, S. C., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., THOMAS, G. V., Workman, P., Kaye, S. B., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.006 · Cited by 89
A Novel Three-Dimensional Immune Oncology Model for High-Throughput Testing of Tumoricidal Activity
Sherman, H., Gitschier, H. J., & Rossi, A. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00857 · Cited by 84
“Yet, these 2D models do not accurately reflect the complexity of a three-dimensional (3D) tumor (4), a characteristic that has been cited as a contributing factor to the high attrition rate of cancer drugs (5, 6).”
Background3S - Systematic, systemic, and systems biology and toxicology
Smirnova, L. (2018) · ALTEX · doi:10.14573/altex.1804051 · Cited by 72
“…in ADME represented a key reason for drug attrition two decades ago (attrition has dropped from 40–60% to nowadays 10% (Kennedy, 1997; Kubinyi, 2003; Kola and Landis, 2004)), as the development of a portfolio of in vitro and in silico tools has drastically improved the situation as reviewed…”
BackgroundConditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
Palechor-Ceron, N., Krawczyk, E., Dakic, A., Simić, V., Yuan, H., Blancato, J. K., Wang, W., Hubbard, F. A., Zheng, Y., Dan, H., et al. (2019) · Cells · doi:10.3390/cells8111327 · Cited by 85
“This at least partially explains that only approximately 5% of oncology drugs developed based on these models and entering clinical trials are eventually approved by the Food and Drug Administration [13].”
BackgroundChoosing The Right Animal Model for Renal Cancer Research
Sobczuk, P., Brodziak, A., Khan, M. I., Chhabra, S., Fiedorowicz, M., Wełniak-Kamińska, M., Synoradzki, K. J., Bartnik, E., Cudnoch‐Jędrzejewska, A., & Czarnecka, A. M. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100745 · Cited by 89
“The major causes of this failure rate in clinics were lack of efficacy (30%) and safety (toxicology and clinical safety amounting to as high as 30% ) [236].”
BackgroundSaxena, V., Panicucci, R., Joshi, Y. M., & Garad, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21592 · Cited by 80
IN VIVO HEPATOTOXICITY STUDY OF RATS IN COMPARISON WITH IN VITRO HEPATOTOXICITY SCREENING SYSTEM
KIKKAWA, R., FUJIKAWA, M., YAMAMOTO, T., HAMADA, Y., YAMADA, H., & HORII, I. (2006) · The Journal of Toxicological Sciences · doi:10.2131/jts.31.23 · Cited by 79
“However, high throughput toxicology, such as in vitro toxicity using small bulk amount has been required for safety evaluation in the early stage of drug discovery (Alden et al., 1999; Luber-Narod et al., 2001; Kola and Landis, 2004; Butcher, 2005).”
BackgroundChoi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 79
“Although issues related to PK and bioavailability have improved since the 2000s [4], nearly half of all the therapeutic candidates in drug development are lost due to poor absorption, distribution, metabolism, excretion (ADME), toxicology, and pharmacology (safety) [5].”
BackgroundZhang, J. D., Berntenis, N., Roth, A., & Ebeling, M. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.39 · Cited by 79
In-Silico Molecular Binding Prediction for Human Drug Targets Using Deep Neural Multi-Task Learning
Lee, K., & Kim, D. (2019) · Genes · doi:10.3390/genes10110906 · Cited by 74
“However, only around 10% of candidate drugs are approved after clinical trials because of a lack of effectiveness or unexpected off-target effects [3,4].”
BackgroundADMET Profiling of Geographically Diverse Phytochemical Using Chemoinformatic Tools
Fatima, S., Gupta, P., Sharma, S., Sharma, A., & Agarwal, S. M. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0206 · Cited by 81
Scheer, N., & Wilson, I. D. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.002 · Cited by 76
Sjogren, A.-K. M., Liljevald, M., Glinghammar, B., Sagemark, J., Li, X., Jonebring, A., Cotgreave, I. A., Brolén, G., & Andersson, T. B. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1265-z · Cited by 85
A luminescent ruthenium( ii ) complex for light-triggered drug release and live cell imaging
Karaoun, N., & Renfrew, A. K. (2015) · Chemical Communications · doi:10.1039/c5cc05172j · Cited by 78
Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 82
“Examining the track record in drug development over the last decade, compared to the preceding ten years, has seen a significant increase in the level of attrition in spite of all the technological advancement and increased investment (Kola & Landis, 2004; Kola, 2008).”
ResultTranslational Research in Cardiovascular Repair
Chamuleau, S. A. J., van der Naald, M., Climent, A. M., Kraaijeveld, A. O., Wever, K., Duncker, D. J., Fernández‐Avilés, F., & Bolli, R. (2018) · Circulation Research · doi:10.1161/circresaha.117.311565 · Cited by 82
Strategy for Extending Half-life in Drug Design and Its Significance
Günaydin, H., Altman, M. D., Ellis, J. M., Fuller, P. H., Johnson, S. A., Lahue, B. R., & Lapointe, B. T. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00018 · Cited by 82
Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation
Parvez, M. M., Basit, A., Jariwala, P. B., Gáborik, Z., Kis, E., Heyward, S. A., Redinbo, M. R., & Prasad, B. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000476 · Cited by 86
“Unpredictable safety and efficacy of investigational drugs has replaced poor pharmacokinetics (PK) as the primary reason for drug attrition during clinical development (Kola and Landis, 2004; Hay et al., 2014).”
BackgroundAlkaloids in Contemporary Drug Discovery to Meet Global Disease Needs
Daley, S.-K., & Cordell, G. A. (2021) · Molecules · doi:10.3390/molecules26133800 · Cited by 88
“Systematic mapping through AI of the action sites at an early stage may yield indications about interactions with other drugs from a synergistic or antagonistic perspective, providing glimpses of potential toxicity issues [302], and should reduce the high levels of attrition occurring in the clinical trials stages [30…”
BackgroundEmerging drugs for neuropathic pain
Gilron, I., & Dickenson, A. H. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.915025 · Cited by 82
“As in other areas of neurotherapeutics [66], much concern has been expressed about the disappointing rates of success for new pain therapeutics at the Phase III stage of drug development [67,68].”
BackgroundExploratory drug safety: A discovery strategy to reduce attrition in development
Bass, A. S., Cartwright, M. E., Mahon, C., Morrison, R. A., Snyder, R. D., McNamara, P., Bradley, P. K., Zhou, Y., & Hunter, J. (2009) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2009.04.194 · Cited by 78
Smith, N. F., Raynaud, F. I., & Workman, P. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0324 · Cited by 83
“Furthermore, failure in the clinic has frequently been due to the same limitations (5, 11).”
BackgroundInfluentialCritical parameters in targeted drug development: the pharmacological audit trail
Banerji, U., & Workman, P. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.06.001 · Cited by 75
Ewart, L., Aylott, M., Deurinck, M., Engwall, M., Gallacher, D. J., Geys, H., Jarvis, P., Ju, H., Leishman, D., Leong, L., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu198 · Cited by 77
“Nonclinical and clinical safety-related terminations together contribute substantially to the overall attrition within drug development (Cook et al., 2014; Kola and Landis, 2004).”
BackgroundFraser, C., Dawson, J. C., Dowling, R., Houston, D. R., Weiss, J. T., Munro, A. F., Muir, M., Harrington, L. A., Webster, S. P., Frame, M. C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00065 · Cited by 82
Early safety assessment of human oculotoxic drugs using the zebrafish visualmotor response
Deeti, S., O’Farrell, S., & Kennedy, B. N. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.09.002 · Cited by 80
“Indeed, of drugs entering clinical development, drug-induced organ toxicity is the leading factor associated with failure to reach the market (Kola & Landis, 2004).”
BackgroundMandenius, C., Steel, D. M., Noor, F., Meyer, T. S., Heinzle, E., Asp, J., Arain, S., Kraushaar, U., Bremer, S., Class, R., et al. (2011) · Journal of Applied Toxicology · doi:10.1002/jat.1663 · Cited by 89
ADMET Property Prediction: The State of the Art and Current Challenges
Gola, J. M. R., Obrezanova, O., Champness, E., & Segall, M. (2006) · QSAR & Combinatorial Science · doi:10.1002/qsar.200610093 · Cited by 83
High throughput microsomal stability assay for insoluble compounds
Di, L., Kerns, E. H., Li, Q. S., & Petusky, S. L. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.007 · Cited by 80
Will we ever be able to accurately predict solubility?
Llompart, P., Minoletti, C., Baybekov, S., Horvath, D., Marcou, G., & Varnek, A. A. (2024) · Scientific Data · doi:10.1038/s41597-024-03105-6 · Cited by 87
“Thus, a better understanding of this property is expected to improve success in drug design 1 , as a key player in pharmacokinetics and ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling 2 .”
Background
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.